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Abstract
Background Pertuzumab (Perjeta), a HER2/neu receptor
antagonist, was approved by the US Food and Drug
Administration in June 2012 for use in the first-line setting
for patients with HER2-positive metastatic breast cancer
(mBC).
Objective This retrospective study investigated the clinical
and demographic characteristics, treatment patterns, safety,
and clinical outcomes for patients with HER2-positive
mBC who received pertuzumab in the first-line setting in
US community oncology practices.
Methods Patients with HER2-positive mBC, who initiated
pertuzumab within 60 days of mBC diagnosis between
June 2012 and June 2014, followed through December
2014, had C2 visits within the McKesson Specialty Health/
US Oncology Network, and were not on clinical trials
during the study period, were eligible. This study utilized
iKnowMed electronic health records, Claims Data Ware-
house, and Social Security Death Index. Progression-free
survival (PFS) was assessed by Kaplan–Meier methods.
Results A total of 266 patients met the selection criteria. A
vast majority of the patients (249/266, 93.6%) received a
trastuzumab ? pertuzumab ? taxane (H ? P ? T) regimen.
The number of patients with prior adjuvant/neoadjuvant
therapy was higher than the CLEOPATRA trial, but age
(median 57 years) and percentage of visceral disease
(74.8%) were similar. The most common adverse events
were fatigue (50.8%), diarrhea (44.7%), nausea (35.3%),
peripheral neuropathy (33.5%), neutropenia (24.9%), and
rash (24.4%). The median PFS was 16.9 months (95% CI
14.2–19.7).
Conclusions In this retrospective study of patients with
HER2-positive mBC receiving pertuzumab in the first-line
setting, most patients were treated with H ? P ? T. The
safety and PFS of H ? P ? T were consistent with those
observed in the pivotal trial.
Key Points
The purpose of this retrospective, observational
study was to investigate the clinical use of
pertuzumab in a population of patients with HER2-
positive mBC treated in a real-world community
oncology practice setting.
We found that most patients were treated with
pertuzumab, trastuzumab, and a taxane in the first-
line setting.
Our results confirmed the clinical safety and PFS of
pertuzumab as first-line therapy for patients with
HER2-positive mBC in the community treatment
setting.
The use of pertuzumab in this setting was consistent
with the NCCN guidelines (2012) and, for the most
part, with the FDA-approved Perjeta (pertuzumab)
prescribing information.
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1 Introduction
Breast cancer is one of the most frequently diagnosed
cancer types, and the second leading cause of death in
women with cancer. It is estimated that in 2016, 246,660
women will have been diagnosed with breast cancer, and
40,450 will have died from the disease [1]. HER2-positive
breast cancer is a subtype that overexpresses the human
epidermal growth factor receptor 2 (HER2) protein that
promotes the growth of cancer cells. Approximately 20%
of breast cancers are HER2-positive (also known as HER2/
neu positive), and overexpression of HER2 is associated
with a poor prognosis [2, 3].
Pertuzumab is a novel HER2/neu receptor antagonist. It
is a humanized monoclonal antibody that binds to HER2
[4]. Preclinical studies have shown that it acts as an anti-
tumor agent by binding to the HER2 receptor and blocking
its pairing with other HER receptors, and is an important
targeted therapy for patients with HER2-positive breast
cancer [5–11]. Pertuzumab was approved by the US Food
and Drug Administration (FDA) in June 2012 to be used in
the first-line setting in combination with trastuzumab and
docetaxel for patients with HER2-positive metastatic breast
cancer (mBC) [12]. The approved pertuzumab dosing
schedule is an initial dose of 840 mg followed every 3
weeks thereafter by 420 mg. The CLEOPATRA Phase 3
trial demonstrated that the addition of pertuzumab to
trastuzumab and docetaxel therapy for HER2-positive
mBC significantly increased the median progression-free
survival (PFS) and overall survival (OS) when compared to
trastuzumab ? docetaxel ? placebo [13, 14]. However,
few reports exist regarding the clinical use, safety, and
effectiveness of pertuzumab for patients with mBC in the
real-world setting.
The purpose of this retrospective, observational study
was to investigate the clinical use of pertuzumab in a
population of patients with HER2-positive mBC treated in
a real-world community oncology practice setting. More
specifically, this study included a description of the
demographics, clinical characteristics, treatment patterns,
and analysis of PFS and adverse events (AEs) for patients




In this retrospective study, demographic, clinical, and
treatment data were primarily abstracted from the
McKesson Specialty Health/US Oncology Network (MSH/
USON) iKnowMed (iKM) electronic health record (EHR)
database. iKM is an oncology-specific, integrated, web-
based system that captures outpatient practice encounter
history for patients treated across 19 US states and at over
400 sites of care. Overall, the iKM EHR database captures
data from approximately 10% of newly-diagnosed cancer
patients in the USA (*750,000) annually and includes
1000 affiliated physicians. MSH/USON’s Claims Data
Warehouse (CDW), which records all health insurance
claims-related information, was used to obtain payer data.
Documented vital status (death) in iKM was supplemented
with data from the Social Security Death Index (SSDI). In
addition, chart reviews were conducted by clinical staff to
supplement and validate data captured by programmatic
queries for prespecified endpoints from the iKM EHR.
2.2 Patient Selection Criteria
Patients with HER2-positive mBC who initiated treatment
with pertuzumab within the study period of 1 June 2012,
and 30 June 2014 were eligible for inclusion in the study.
All patients were followed through 31 December 2014 (end
of study follow-up). The primary analysis population met
the following criteria: (1) female patients with HER2-
positive mBC; (2) had at least two visits within USON
during the study period; (3) received care at a practice
utilizing the full EHR capabilities of iKM; (4) C18 years
old at diagnosis; and (5) received pertuzumab within 60
days of mBC diagnosis during the study period. Patients
were excluded if they were diagnosed with or treated for
another primary cancer during the study period, or were
concurrently enrolled in a clinical trial.
2.3 Measures
The date of initiation of pertuzumab was defined as the
index date. PFS was defined as the time from the index date
until the first disease progression, or death from any cause,
whichever occurred earlier. Evidence of progression was
captured from chart review. Patients without a progression
or death event were censored at the last pertuzumab
administration date within the study period, last visit date,
or the end of study-follow up, whichever occurred first.
Adverse events were captured from the index date until
30 days after the pertuzumab discontinuation date, or the
end of study follow-up, whichever occurred first. Per-
tuzumab treatment duration was defined as the time from
the index date to the last pertuzumab administration date,
last visit date, death date, or the end of study-follow up,
whichever occurred first.
The Eastern Cooperative Oncology Group (ECOG)
performance status at index was recorded for each patient.
Comorbidities noted within 6 months prior to the index
date were included, and assigned a weight based on the
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Charlson Comorbidity Index (CCI). Disease type at diag-
nosis was classified as non-visceral if the metastatic sites
were breast, bone/bone marrow, lymph node, skin, or chest
wall, or visceral if the metastatic sites were adrenal gland,
ascites, brain, cervix, esophagus, gall bladder/bile duct,
head and neck localized lesion, kidney, liver, lung, medi-
astinum, ovary, pancreas, pelvis (non-bone), pericardial
effusion, rectum, trachea/bronchi, uterus, or other. Patients
with both visceral and non-visceral metastatic sites were
considered to be a part of the visceral subset. Among
patients with recurrent disease, disease-free interval (DFI)
was calculated as the duration from date of primary breast
cancer surgery to mBC diagnosis.
2.4 Statistical Analysis
All statistical analyses were conducted on the primary
analysis population. Descriptive statistics were utilized to
summarize demographics, clinical characteristics, treat-
ment patterns, and AEs. Categorical variables were repor-
ted as frequency and percentage, and continuous variables
were reported as mean, standard deviation, median, and
range. Since docetaxel was the taxane used in the CLEO-
PATRA pivotal trial [13, 14], and as trastuzumab ? per-
tuzumab ? docetaxel is also the FDA-approved indicated
regimen in the mBC setting [12], a sensitivity analysis was
performed on a subset of the primary analysis population
who initiated treatment with trastuzumab ? pertuzumab ?
docetaxel. Kaplan–Meier (KM) survival analyses were
conducted to estimate median PFS, and PFS rates with their
corresponding 95% confidence intervals (CIs) at 6, 9, 12,
and 18 months, for the primary and sensitivity analysis
populations. All statistical analyses were performed using
SAS 9.2 (SAS Institute, Cary, NC, USA).
3 Results
3.1 Patient Characteristics
The primary analysis population, i.e., patients with HER2-
positive mBC who initiated pertuzumab within 60 days of
mBC diagnosis, included 266 patients. Mean (SD) age was
57 (13.7) years (Table 1). The majority of the population
was Caucasian (70.7%), and had private insurance (63.1%).
ECOG performance status was 0 or 1 for 83.9% of patients,
and CCI was 0 for 78.2% of the patients. Visceral disease
was noted for 74.8% of patients. About one-half of the
patients (49.2%) had de novo mBC. Among patients with
recurrent mBC, the median DFI was 33.7 months (range
3.8–471.8) and 61.5% (83/135) of these patients previously
received trastuzumab in the adjuvant/neoadjuvant setting.
The most common sites of metastases were lymph node
(63.5%), bone/bone marrow (52.6%), liver (43.6%), and
lung (32.3%). Around 60% of patients had tumors that
were ER-positive and/or PgR-positive.
A subgroup of 221 patients (83.1% of 266 patients)
constituted the sensitivity analysis population, i.e., initiated
trastuzumab ? pertuzumab ? docetaxel within 60 days of
mBC diagnosis. The remaining 45 patients were excluded
from the sensitivity analysis population for the following
reasons: five patients received docetaxel after 60 days of
mBC diagnosis, 39 did not receive docetaxel, and one
patient received ado-trastuzumab emtansine instead of
trastuzumab.
3.2 Treatment Patterns
The median duration between the date of mBC diagnosis
and that of pertuzumab initiation was 26 days (range 0–60
days). Of the 266 patients, 265 received pertuzumab in
combination with trastuzumab, with one patient having
received ado-trastuzumab emtansine instead of trastuzu-
mab. The majority of the patients (N = 249/265, 94.0%)
received trastuzumab with pertuzumab plus a taxane. Of
the remaining patients, 14 (5.3%) patients did not receive
any chemotherapy while 2 (0.7%) received vinorelbine. All
patients received the indicated pertuzumab loading dose of
840 mg, with the exception of one who received 420 mg
instead, and all received the indicated maintenance dose of
420 mg. The median number of cycles of pertuzumab
administered was 11 (range 1–41), and the median per-
tuzumab treatment duration was 7.3 months (range
0.7–29). Among the patients receiving a taxane as their
initial chemotherapy (N = 249), 226 (90.8%) received
docetaxel, 21 (8.4%) received paclitaxel, and two (0.8%)
received nab-paclitaxel. The median number of cycles of
docetaxel administered was 6 (range 1–27), and the median
duration of docetaxel was 4.1 months (range 0.7–21.9). At
the time of this analysis, 38 (14.3%) patients were noted to
have received endocrine therapy in the first-line setting.
Thus, up to the point of this data cut-off, 24.5% of the
patients with hormone receptor-positive disease had
received endocrine therapy.
Through the end-of-study follow-up, pertuzumab was
discontinued in 170 of the 266 patients (63.9%). The most
common reasons for pertuzumab discontinuation were dis-
ease progression (N = 76, 28.6%), loss to follow-up (N = 28,
10.5%), toxicity (N = 19, 7.1%), and death (N = 12, 4.5%).
3.3 Clinical Outcomes
The most common AEs were fatigue (50.8%), followed by
diarrhea (44.7%), nausea (35.3%), and peripheral neu-
ropathy (33.5%) (Table 2). Some patients (N = 17, 6.4%)
were noted to have been hospitalized due to AEs.
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Prophylactic G-CSF use (defined as use during the first
cycle of chemotherapy) was noted in 70 (26.3%) patients.
The median duration from pertuzumab initiation to end-
of-study follow-up was 16.4 months (range 6.2–30.2). The
median PFS was 16.9 months (95% CI 14.2–19.7) for the
primary analysis population, as demonstrated in Fig. 1, and
the estimated PFS rate at 1 year was 62.1% (95% CI
54.6–68.7). For the sensitivity analysis population, the
median PFS was 16.9 months (95% CI 13.9–20.1), and the
estimated PFS rate at 1 year was 62.5% (95% CI
54.2–69.7), as shown in Fig. 2.
4 Discussion
The results of CLEOPATRA demonstrated improved out-
comes in trastuzumab ? pertuzumab ? docetaxel com-
pared to trastuzumab ? docetaxel ? placebo, which has led
to trastuzumab ? pertuzumab ? docetaxel becoming the
new standard treatment regimen for HER2-positive mBC
in the first-line setting [13–16]. These study findings led to
Table 1 Patient baseline demographics and disease characteristics
Characteristics N = 266
N (%)
Age at metastatic breast cancer diagnosis (years)




\65 years old 188 (70.7)














Black/African American 33 (12.4)
Asian 14 (5.3)
Native American 1 (0.4)
Hispanic 4 (1.5)
Other 2 (0.7)
No information 24 (9.0)
Metastatic breast cancer diagnosis
Recurrent mBC 135 (50.8)
de novo mBC 131 (49.2)
Disease-free interval (months)
N 135 (50.8)
Mean (SD) 51.4 (57.6)
Median 33.7
Min–max 3.8–471.8
Inflammatory breast cancer (IBC)
IBC disease 27 (10.2)
Non-IBC disease 239 (89.8)
Skin/chest wall involvement
Skin 39 (14.7)








No information 6 (2.2)
Table 1 continued





No information 1 (0.4)
Hormone receptor status
ER and PgR negative 111 (41.7)
ER and/or PgR positive 155 (58.3)
ECOG performance status (PS)
PS 0 64 (24.1)
PS 1 159 (59.8)
PS 2 30 (11.3)
PS 3 4 (1.5)
No information 9 (3.4)










SD standard deviation, DFI disease-free interval, IBC inflammatory
breast cancer, ER estrogen receptor, PgR progesterone receptor,
ECOG Eastern Cooperative Oncology Group, PS performance status
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the US FDA approval of the use of pertuzumab in com-
bination with trastuzumab and docetaxel for the treatment
of patients with HER2-positive metastatic breast cancer
who have not received prior anti-HER2 therapy or
chemotherapy for metastatic disease. In 2014, the Ameri-
can Society of Clinical Oncology (ASCO) Clinical Practice
guidelines recommended pertuzumab and trastuzumab in
combination with a taxane chemotherapy as the preferred
option for first-line therapy of HER2-positive mBC [17].
The findings of our study are consistent with the CLEO-
PATRA trial results—the PFS of the primary and sensi-
tivity analysis populations are both quite similar to that
observed in the randomized clinical trial.
In this retrospective study, we looked at the clinical and
demographic characteristics, treatment patterns, safety, and
PFS in a population of patients with HER2-positive mBC
who received pertuzumab in the first-line setting in com-
munity oncology practices, the US Oncology Network.
Between June 2012 and June 2014, a total of 266 patients
with HER2-positive mBC initiated pertuzumab based
therapy with 221 patients who started treatment with tras-
tuzumab ? pertuzumab ? docetaxel. The other
chemotherapy drugs given were paclitaxel, nab-paclitaxel,
vinorelbine, carboplatin, capecitabine, or gemcitabine. The
median duration of treatment with pertuzumab was 7.3
Table 2 Incidence of select adverse eventsa









Decreased appetite 37 (13.9)
Constipation 35 (13.2)
Mucosal inflammation 33 (12.4)





Febrile neutropenia 6 (2.3)
Dry skin 4 (1.5)
Hypersensitivity 4 (1.5)
Left ventricular dysfunction 2 (0.8)
Cardiovascular event 0
a Any adverse events regardless of grade
Number of 
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Fig. 1 Progression-free survival (PFS) from initiation of pertuzumab (Kaplan–Meier analysis)—primary analysis population
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months (range 0.7–29). The pertuzumab fixed dose was as
in the prescribing information. At 1 year, the estimated PFS
rate for patients who initiated pertuzumab was 62.1%, and
for those who started trastuzumab ? pertuzumab ? doc-
etaxel was 62.5%. We found that similar to the pivotal
clinical trial, the chemotherapy component was adminis-
tered for a limited period, with patients then continuing
with pertuzumab and trastuzumab. Unlike the CLEOPA-
TRA trial in which endocrine therapy was not permitted,
endocrine therapy was used in at least 24.5% of patients
with hormone receptor-positive tumors.
There are some differences with our population com-
pared to the CLEOPATRA trial. There was a greater use of
adjuvant/neoadjuvant trastuzumab (61.5 vs. 38.6%). The
age and percentage of visceral disease were similar in both
groups. Regarding AEs, there were fewer side effects
reported, but this is probably due to the retrospective nature
of this analysis, which is unlike the emphasis of reporting
of side effects, including low-grade ones, in a randomized
clinical trial. Cardiac toxicities were minimal, which is in
accordance with previous studies [18, 19], and there were
no CNS toxicities noted.
The strengths of this study include the inclusion of
recent data, the ability to observe patients longitudinally
over time, and the use of EHRs, which include much more
detailed information on medication use than the medical
claims often used in studies of this nature. The results
provide insights into the real-world use of pertuzumab in
the first-line setting among patients with HER2-positive
mBC in a rapidly changing therapeutic environment char-
acterized by the recent introduction of new treatment
options and the nearly continuous updating of best prac-
tices based on emerging data from clinical trials. Our study
is subject to inherent limitations of retrospective analyses
based on electronic medical records, in that databases may
contain inaccurate or missing data. This study utilized
abstraction from unstructured clinical notes to assess for
and confirm pre-specified endpoints which can be suscep-
tible to error and bias. Finally, progression was evaluated
by the treating physicians with the assessments done per
the individual physician’s standard-of-care, which may be
subjected to their own judgment. Also in this study, only
univariate analyses were conducted; further investigation
with a larger population, longer follow-up time, and mul-
tivariate analyses is warranted.
5 Conclusions
In this retrospective study of a real-world setting utilizing
pertuzumab as part of the first-line therapy of HER2-pos-
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Fig. 2 Progression-free survival from initiation of pertuzumab (Kaplan–Meier analysis)—sensitivity analysis population
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pertuzumab, trastuzumab, and a taxane. The dose and
frequency of pertuzumab administration were consistent
with the prescribing information. Our results confirmed the
clinical safety and PFS of pertuzumab as first-line therapy
for patients with HER2-positive mBC in the community
treatment setting. Moreover, the use of pertuzumab in this
setting was consistent with the NCCN guidelines and, for
the most part, with the FDA-approved Perjeta (per-
tuzumab) prescribing information.
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